Key facts
- ImmunitoAI’s last known valuation is $21.4M (Nov 2025).
- It has raised $9.1M; the latest was Later Stage VC ($6.1M) in Nov 2025.
- Notable investors include Google for Startups, Entrepreneurs First, LetsVenture Technologies, Anicut Capital, 3one4 Capital — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for ImmunitoAI
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmunitoAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmunitoAI
Developer of an AI-powered platform for antibody discovery intended to accelerate the development of novel antibody therapeutics. The company's platform offers novel antibody and antibody fragments against any epitope and does not depend upon a biological source, animal or human, for the lead molecule, and antibody therapeutics with pre-defined drug properties, enabling healthcare institutions to save time and money and increase efficiency.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2020
- Employees
- 23
- Website
- immunitoai.com/
- Ownership
- Privately Held (backing)
ImmunitoAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunitoAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunitoAI in its N-PORT filings yet. We sweep new filings monthly.